AKT2 and breast cancer: All events triggered by miR-126-3p-mediated downregulation of AKT2 seem to be functional in both receptor positive and negative BC cells, as superimposable effects were found in TNBC subtype (BT549 cells) and in a less aggressive Luminal A (MCF-7 cells) subtype.